SCHEMBL6799329

SCHEMBL6799329

CC(=O)c1cc(Cl)sc1N1CCN(C)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
RAB9A P51151 5/20 0.39
NPC1 O15118 3/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSP90AA1 P07900 1/20 0.37
TP53 P04637 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
HPGD P15428 2/20 0.37
DAO P14920 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799336 0.86 TSHR (0.41) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL8080463 0.84 WDR5 (0.40) KMT2AMEN1RAB9ASMN1; SMN2KDM4E
SCHEMBL6804364 0.83 PRKDC (0.48) RAB9ANPC1MAPTLMNASMN1; SMN2
SCHEMBL14598726 0.78 POLB (0.44) KMT2AMEN1MAPTLMNASMN1; SMN2
SCHEMBL6803709 0.74 PLOD2 (0.42) HRH4KMT2AMEN1SMN1; SMN2KDM4E
SCHEMBL1481336 0.69 POLB (0.58) KMT2AMEN1RAB9AMAPTLMNA
SCHEMBL1481913 0.69 RAB9A (0.53) KMT2ARAB9ANPC1MAPTLMNA
SCHEMBL542159 0.68 DAO (0.65) KMT2ARAB9ANPC1MAPTLMNA
SCHEMBL25009968 0.67 KDM4E (0.51) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL12932972 0.67 WDR5 (0.42) RAB9ANPC1MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds PFIZER INC. 2004-07-22 US disclosed
US-6696470-B2 FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. PFIZER INC. 2004-02-24 US disclosed
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds KAWAI AKIYOSHI (JP) 2002-02-21 US disclosed
EP-0853083-B1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER (US) 2001-09-12 EP disclosed
US-6048880-A THERAPY FOR CYTOKINE SENSITIVE DISEASES PFIZER PHARAMACEUTICALS INC. (JP) 2000-04-11 US disclosed
EP-0853083-A1 Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof PFIZER INC. (US) 1998-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142976-A1 Pyridylfuran and pyridylthiophene compounds MC2R, FCGR2A, OGFR HRH4 302/4885KMT2A 4178/4885MEN1 4744/4885
US-20020022729-A1 Pyridylfuran and pyridylthiophene compounds MC2R, CRHR1, NR3C2 HRH4 157/4885KMT2A 4224/4885MEN1 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.